OptiNose

OptiNose — Investor Presentation (March 2018)

26 slides from OptiNose's investor presentation, Mar 13, 2018

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company Corporate Presentat ion M a r c h 1 3 , 2 0 1 8

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this

  3. Slide 3: Emerging Growth Company with Approved Products

    3 Emerging Growth Company with Approved Products BUILDING A LEADING ENT / ALLERGY SPECIALTY COMPANY • 3.5 Million CRS patients (1.2M with nasal polyps) being treated by 15,000 physicians • Limited competition anticipated from any pharma companies at launch XHANCE Represents a Significant Opportunity

  4. Slide 4: Successful Launches Driven by Four Key Factors

    4 Our Research on Over 300 Products Suggests Successful Launches are Driven by Four Key Factors Market Access Attractive Market…with High Unmet Need Differentiated Product Awareness / Execution

  5. Slide 5: Large CRS Population with Severe Symptoms

    5 Mild Moderate Severe • Highly prevalent in the United States (~65M) • Largely OTC / generic market • Well-treated using INS Allergic Rhinitis * Based on US Adult Population Survey (n=10,336). • ~30M US adults suffer from CRS—up to 10M with Nasal Polyps • 9.75M patients actively seeking physician c

  6. Slide 6: Chronic Rhinosinusitis (CRS) With or Without Polyps

    6 A diagnosis characterized by chronic inflammation • Disease persists for many years • Significant quality of life impact (comparable to CHF, COPD, Angina) • Symptoms Include: congestion and blocked nose, purulent drainage, facial pain/pressure, loss of sense of smell, chronic sleep problems, heada

  7. Slide 7: Existing Treatments Are Often Sub-Optimal

    7 High Cost, Typically Not Curative Sinus Surgery Up to 80% of patients may continue to have symptoms post-surgery Continued INS use after surgery is typical $8,500–$16,000 per procedure, and repeat surgery is not uncommon Limited Efficacy Medical Management Saline nasal sprays, irrigation, neti pot

  8. Slide 8: A Breakthrough Approach to Nasal Delivery

    8 Problem: Nasal sprays and aerosols do not effectively place drug high and deep in the nasal passages Solution: Unique new concept for delivery gets medicine to targeted sites of inflammation Drug released into airflow Pressure balances Soft palate closes Blow into device Press bottle up to open de

  9. Slide 9: Optinose EDS Can Deliver Drug High & Deep in the Nose

    9 Optinose EDS w/Exhalation Nasal Spray w/o Exhalation Intranasal steroids are TOPICALLY ACTING medications: Delivery to sites of chronic inflammation and nasal polyp origin is important Sinus drainage regions are key treatment targets Optinose EDS Can Deliver Drug High & Deep in the Nose KEY TO TRE

  10. Slide 10: Differentiated Clinical Profile

    10 Trial Type N Sites NAVIGATE I Phase 3 Pivotal 323 54 NAVIGATE II Phase 3 Pivotal 323 38 EXHANCE-3 Phase 3 open-label 3 month 700 38 EXHANCE-12 Phase 3 open-label 12 month 223 21 Study 1102 Phase 1 bioavailability 112 2 Global Clinical Program* Improvement on all four defining symptoms of CRS Redu

  11. Slide 11: Commercialization Strategy - Build XHANCE into a Leading Product

    11 WAVE 1 Enter High-Density ENT/Allergy Specialty Market • 14,000 Physician Targets • 80 Sales Reps Ramping up to 120 • Additional 1,000 physicians targeted through digital and non-personal promotion • Limited Competition • Promotion of Nasal Polyp Indication ~3.5M Patients (1.2M with Nasal Polyps)

  12. Slide 12: 30 Million U.S. Adults Suffer from Chronic Rhinosinusitis

    12 96.1% 0 5 10 15 20 25 30 35 40 45 Database Population % of Population with no CRS Claim % of Population with CRS Claim P at ie n t Cla im s Da ta b as e 41M 3.9% 30 Million U.S. Adults Suffer from Chronic Rhinosinusitis ~9.75M PATIENTS CURRENTLY UNDER ACTIVE CARE OF A PHYSICIAN FOR CRS Approximat

  13. Slide 13: Pricing Landscape Offers Attractive Scenarios

    13 * BID dosing required for the treatment of nasal polyps, based upon Nasonex data and academic literature. WAC prices reflect a 2x multiple on the WAC price for conventional INS due to the approved dose for the treatment of nasal polyps. ^ Nasonex and Mometasone are currently the only other intran

  14. Slide 14: Total Market Opportunity of >$9.5B

    14 PREVALENCE OVERALL TREATED PATIENTS TREATED PATIENTS IN SEGMENT TOTAL ANNUAL US MARKET OPPORTUNITY SEGMENT ANNUAL MARKET OPPORTUNITY INCREMENTAL PCP OPPORTUNITY (1) Target market represents ~10,000 ENT and allergy specialists and ~5,000 high-decile INS prescribing primary care physicians. (2) Bas

  15. Slide 15: Differentiated Physician Reaction to Profile

    15 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Allergists ENTs PCPs Li ke lih o o d t o P re scri b e N=200 N=202 N=302 Percent of HCPs stating they will definitely or probably prescribe a product profile similar to XHANCE Differentiated Physician Reaction to Profile SUGGESTS HIGH LAUNCH INTEREST AND ‘ST

  16. Slide 16: Introducing XHANCE

    16 Introducing XHANCETM Retail Launch Expected in Early April…

  17. Slide 17: Launch Execution Priorities

    17 Awareness, Trial and Adoption Market Access Brand Differentiation Commercial Capabilities LAUNCH EXECUTION PRIORITIES

  18. Slide 18: Commercial Capabilities

    18 Commercial Capabilities Hired an experienced first-line sales leadership team Recruited & trained fully-dedicated contract territory managers (TMs) Experienced Sales Team Optimally Deployed to Accelerate Adoption of XHANCE at Launch ~8,000 HCPs targeted at launch Growing to ~14,000 based on expan

  19. Slide 19: Awareness, Trial and Adoption

    19 Awareness, Trial and Adoption Social media: reached 10,000 ENTs and allergists and delivered 700,000 impressions Multi-Channel Integrated Marketing Program Increased Aided Awareness to Over 73% in the Past 4 Months Initial reaction from target physicians to core brand messages is positive Launche

  20. Slide 20: XHANCE Xperience Program

    20 XHANCE Xperience Program- Initiated in Market on 3/5 ▪ Limited availability program offering select physicians and their patients an opportunity to gain initial experience with XHANCE ▪ Enrolled patients receive up to two prescription fills of XHANCE at no cost to them ($0 co-pay) ▪ A full-servic

  21. Slide 21: Market Access on Track to Support Retail Launch

    21 Market Access on Track to Support Retail Launch Market Access Engaged with 40 payers representing 85% of commercial lives Objective is to achieve 75% tier 3 market access for commercial lives by YE 2018 Covered Commercial Lives at Launch Favorable health system economics (e.g., surgical cost savi

  22. Slide 22: Strong Foundation for a Successful Launch in 2018

    22 Market Access Current Patients Dissatisfied with Existing Treatment Physician Dissatisfaction with Current Treatments Attractive Market…with High Unmet Need Differentiated Product Physician Stated Interest to Prescribe Covered Commercial Lives at Launch Awareness / Execution Awareness During Laun

  23. Slide 23: Chronic Sinusitis Follow-on Indication (sNDA)

    23 Chronic Sinusitis Follow-on Indication (sNDA) Plan to submit protocol to FDA in 1H 2018 Selection of CRO and study locations First patients expected to enroll in 4Q 2018 Phase 3b trial design expected to include co-primary endpoints: both an objective measure of inflammation and a subjective meas

  24. Slide 24: Key Objectives for 2018

    24 Achieve greater than 85% aided awareness of XHANCE in target ENT and allergist audience during retail launch Secure market access for XHANCE ≥65% of patients with commercial insurance plans at retail launch expanding to 75% by year end Successfully launch XHANCE in April 2018 Initiate clinical st

  25. Slide 25: Investor Relations – Analyst Coverage

    25 Investor Relations – NASDAQ: OPTN Analyst Coverage1 BMO: Gary Nachman Jefferies: David Steinberg Piper Jaffray: David Amsellem RBC: Randall Stanicky Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Operations 267-521-0531 1 - Optinose is followed by the analysts liste

  26. Slide 26: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company Corporate Presentat ion M a r c h 1 3 , 2 0 1 8

OptiNose — Investor Presentation (March 2018) on 6ix